To gain further insight into the impact of recombinant oncolytic PRV application on the tumor microenvironment, tumor tissues were harvested on the 23rd day and subjected to immunohistochemical staining for CD4+T cells, CD8+T cells and hyaluronidase. The gene discussed is CD4; the disease is neoplasm.